Novartis

E_DEPRECATED Error in file �functions_general.php� at line 326: Function utf8_encode() is deprecated

E_DEPRECATED Error in file �functions_general.php� at line 326: Function utf8_encode() is deprecated Novartis logo

E_DEPRECATED Error in file �functions_general.php� at line 186: Function utf8_encode() is deprecated

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

Keywords:

Date	News
2020-02-11	Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-sma...
2020-01-31	Novartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitis
2020-01-31	Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market ...
2020-01-29	Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
2020-01-20	Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis ...
2020-01-09	Novartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic...
2020-01-06	Novartis completes tender offer for all outstanding shares of The Medicines Company
2020-01-06	Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigation...
2019-12-16	Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
2019-12-13	Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD

Date

News

2020-02-11

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-sma...

2020-01-31

Novartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitis

2020-01-31

Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market ...

2020-01-29

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

2020-01-20

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis ...